Materiały źródłowe

• #1 Cervical Cancer Prognosis and Survival Rates – NCI

  https://www.cancer.gov/types/cervical/survival

  If you have been diagnosed with cervical cancer, you may have questions about how serious the cancer is and your chances of survival. The likely outcome or course of a disease is called prognosis. […] The prognosis for cervical cancer depends on many factors: the stage of the cancer (the size of the tumor and whether the cancer has spread beyond the cervix), the type of cervical cancer (adenocarcinoma or squamous cell carcinoma), your age and general health, whether you have other health problems or diseases, including if you are immunocompromised or have HIV, whether the cancer is newly diagnosed or has recurred (come back). […] Doctors estimate cervical cancer prognosis by using statistics collected over many years from people with cervical cancer. One statistic that is commonly used in making a prognosis is the 5-year relative survival rate. The 5-year relative survival rate tells you what percent of people with the same type and stage of cervical cancer are alive 5 years after their cancer was diagnosed, compared with people in the overall population. For example, the 5-year relative survival rate for cervical cancer diagnosed at an early stage is 91%. This means that people diagnosed with early-stage cervical cancer are 91% as likely as people who do not have cervical cancer to be alive 5 years after diagnosis. The 5-year relative survival rates for cervical cancer are as follows: When cervical cancer is diagnosed at an early stage, the 5-year relative survival rate is 91%. When cervical cancer is diagnosed after it has spread to nearby tissues, organs, or regional lymph nodes, the 5-year relative survival rate is 60%. When cervical cancer is diagnosed after it has spread to a distant part of the body, the 5-year relative survival rate is 19%. The 5-year relative survival rate for all people with cervical cancer is 67%. […] Because prognosis statistics are based on large groups of people, they cannot be used to predict exactly what will happen to you. The doctor who knows the most about your situation is in the best position to discuss these statistics and talk with you about your prognosis.

• #2 Prognosis and survival for cervical cancer | Canadian Cancer Society

  https://cancer.ca/en/cancer-information/cancer-types/cervical/prognosis-and-survival

  If you have cervical cancer, you may have questions about your prognosis. A prognosis is the doctors best estimate of how cancer will affect someone and how it will respond to treatment. Prognosis and survival depend on many factors. Only a doctor familiar with your medical history, the type and stage and other features of the cancer, the treatments chosen and the response to treatment can put all of this information together with survival statistics to arrive at a prognosis. […] A prognostic factor is an aspect of the cancer or a characteristic of the person (such as their age or whether they smoke) that the doctor will consider when making a prognosis. A predictive factor influences how a cancer will respond to a certain treatment. Prognostic and predictive factors are often discussed together. They both play a part in deciding on a treatment plan and a prognosis.

• #3 Cervical Cancer: Your Chances for Recovery (Prognosis) | Saint Luke’s Health System

  https://www.saintlukeskc.org/health-library/cervical-cancer-your-chances-recovery-prognosis

  Prognosis is the word your healthcare team may use to describe your chances of recovering from cancer. Or it may mean your likely outcome from cancer and cancer treatment. […] A doctor who is most familiar with your health is in the best position to discuss your prognosis with you and explain what the statistics may mean in your case. At the same time, you should keep in mind that your prognosis can change. Cancer and cancer treatment outcomes are hard to predict. […] If your cancer is likely to respond well to treatment, your doctor will say you have a favorable prognosis. This means you’re expected to live many years and may even be cured. If your cancer is likely to be hard to control, your prognosis may be less favorable. The cancer may shorten your life. […] The survival rates for cervical cancer are based on 5 years. Many women included in the 5-year rate live much longer than 5 years after diagnosis.

• #3 Cervical Cancer: Your Chances for Recovery (Prognosis) | Saint Luke’s Health System

  https://www.saintlukeskc.org/health-library/cervical-cancer-your-chances-recovery-prognosis

  The majority of women diagnosed with cervical cancer in the U.S. are cured. Newly diagnosed women often have a better outlook because of improvements in treatment. […] The 5-year survival rates for cervical cancer are: 68% for all stages of cervical cancer combined […] 91% when invasive cervical cancer is found at an early stage. (It’s only in the cervix. It has not spread.) […] 57% if the cancer is found after it has already spread to nearby tissues and lymph nodes […] 17% if the cancer has spread to distant parts of the body.

• #4 Survival statistics for cervical cancer | Canadian Cancer Society

  https://cancer.ca/en/cancer-information/cancer-types/cervical/prognosis-and-survival/survival-statistics

  Survival statistics for cervical cancer are very general estimates and must be interpreted very carefully. Because these statistics are based on the experience of groups of people, they cannot be used to predict a particular persons chances of survival. […] In Canada, the 5-year net survival for cervical cancer is 74%. This means that about 74% of women diagnosed with cervical cancer will survive for at least 5 years. […] Survival varies with each stage of cervical cancer. Generally, the earlier cervical cancer is diagnosed and treated, the better the outcome. […] The 5-year survival rate is the percentage of people who are alive at least 5 years after their cancer diagnosis. But women with this type of cancer may live much longer than 5 years. […] Talk to your doctor about your prognosis. A prognosis depends on many factors, including: your health history, the type of cancer, the stage, certain characteristics of the cancer, the treatments chosen, how the cancer responds to treatment. […] Only a doctor familiar with these factors can put all of this information together with survival statistics to arrive at a prognosis.

• #5 Cervical Cancer Survival | Cervical Cancer Survival Rate

  https://www.cancerresearchuk.org/about-cancer/cervical-cancer/survival

  Survival depends on many factors. No one can tell you exactly how long you will live. […] Your outlook (prognosis) depends on the stage of your cancer at diagnosis. […] Around 95 out of 100 people (around 95%) will survive their cancer for 5 years or more after diagnosis. […] Almost 70 out of 100 people (almost 70%) will survive their cancer for 5 years or more after diagnosis. […] More than 40 out of 100 people (more than 40%) will survive their cancer for 5 years or more after diagnosis. […] Around 15 out of 100 people (around 15%) will survive their cancer for 5 years or more after being diagnosed. […] Generally, for people with cervical cancer in England: more than 80 out of every 100 (more than 80%) will survive their cancer for 1 year or more after they are diagnosed; around 60 out of every 100 (around 60%) will survive their cancer for 5 years or more after diagnosis; around 50 out of every 100 (around 50%) will survive their cancer for 10 years or more after diagnosis.

• #6 Prognosis and survival for cervical cancer | Canadian Cancer Society

  https://cancer.ca/en/cancer-information/cancer-types/cervical/prognosis-and-survival

  The following are prognostic and predictive factors for cervical cancer. […] Spread of the cancer to the lymph nodes is one of the most important prognostic factors. Cervical cancer that has not spread to lymph nodes has a better prognosis than cervical cancer that has spread to lymph nodes. […] The stage of cervical cancer is an important prognostic factor. Early stage cervical cancer has a better prognosis than later stage cervical cancer. Tumours that grow into the sides of the pelvis, the connective tissue around the cervix and uterus or other areas in the body have poorer outcomes than cancer that is only in the cervix. […] Lymphovascular invasion means that there is cancer in the tumours blood vessels or lymph vessels (tubes through which lymph fluid travels in the body). Cancer that has not spread into the blood or lymph vessels is linked with a better prognosis than cancer that has spread to the blood or lymph vessels.

• #7 Prognostic Model for Predicting Overall and Cancer-Specific Survival Among Patients With Cervical Squamous Cell Carcinoma: A SEER Based Study

  https://pmc.ncbi.nlm.nih.gov/articles/PMC8317021/

  Clinical stage is the most important prognostic factor for CSCC. However, clinical stage does not fully reflect the biological heterogeneity of CSCC. […] Cox regression analysis showed that clinical stage and tumor size are independent prognostic factors for both OS and CSS, and these two factors are also the top two factors influencing the final risk score for OS and CSS in our nomograms, consistent with previous studies. […] In conclusion, we used the SEER database to analyze prognostic data for CSCC patients, identified independent prognostic factors, and constructed nomograms for estimating the 3- and 5-year OS and CSS. Internal and external validation showed that the model has satisfactory predictive performance and may be considered as a reliable tool to predict prognosis.

• #7 Prognostic Model for Predicting Overall and Cancer-Specific Survival Among Patients With Cervical Squamous Cell Carcinoma: A SEER Based Study

  https://pmc.ncbi.nlm.nih.gov/articles/PMC8317021/

  Cervical squamous cell carcinoma (CSCC) is the most common histological subtype of cervical cancer. The purpose of this study was to assess prognostic factors and establish personalized risk assessment nomograms to predict overall survival (OS) and cancer-specific survival (CSS) in CSCC patients. […] Age, race, histologic grade, clinical stage, tumor size, chemotherapy and historic stage were assessed as common independent predictors of OS and CSS. The C-index value of the nomograms for predicting OS and CSS was 0.771 (95% confidence interval 0.762-0.780) and 0.786 (95% confidence interval 0.777-0.795), respectively. Calibration curves of the nomograms indicated satisfactory consistency between nomogram prediction and actual survival for both 3-year and 5-year OS and CSS. […] We constructed nomograms that could predict 3- and 5-year OS and CSS of CSCC patients. These nomograms showed good performance in prognostic prediction and can be used as an effective tool to evaluate the prognosis of CSCC patients, thus contributing to clinical decision making and individualized treatment planning.

• #8 Prognostic Significance of Lymph Node Involvement in Cervical Cancer Patients with Negative Post-Treatment PET Scans | Journal of Nuclear Medicine

  https://jnm.snmjournals.org/content/65/supplement_2/242237

  The FIGO/TNM staging system, with emphasis on lymph node involvement, is vital in cervical cancer prognosis. […] Our study highlighted the crucial interplay of lymph node involvement in influencing clinical disease-free survival. Notably, Gradient Boosting, Ridge, and XGBoost machine learning demonstrated superior predictive performance, underscoring their potential as effective models for prognosis in this specific patient population. These findings offer valuable insights to enhance outcomes in the management of cervical cancer, particularly for patients with node involvement in pre-treatment PET scans whose post-treatment PET results are negative.

• #9 Classical Prognostic Factors Predict Prognosis Better than Inflammatory Indices in Locally Advanced Cervical Cancer: Results of a Comprehensive Observational Study including Tumor-, Patient-, and Treatment-Related Data (ESTHER Study)

  https://www.mdpi.com/2075-4426/13/8/1229

  In order to improve the outcome prediction, and therefore to allow treatment modulation based on the prognostic profile, recent investigations evaluated the predictive role of several systemic inflammation indices which were found to be significantly correlated with the therapeutic outcome in several cancers. […] Our analysis showed no significant correlation between indices and DSF or OS. […] In a comprehensive analysis of inflammatory indices and patient-, tumor-, treatment-, and nutrition-related parameters, the negative prognostic impact of older age, advanced FIGO stage, lower hemoglobin levels, and largest tumor size was recorded in LACC patients treated with CRT plus BRT boost. […] Our analysis did not show an impact of PNI on any of the evaluated endpoints, contrary to what was recorded in a previous study.

• #9 Classical Prognostic Factors Predict Prognosis Better than Inflammatory Indices in Locally Advanced Cervical Cancer: Results of a Comprehensive Observational Study including Tumor-, Patient-, and Treatment-Related Data (ESTHER Study)

  https://www.mdpi.com/2075-4426/13/8/1229

  Our study has obvious limitations. The number of analyzed patients, although relatively large, at least for some subgroup analyses may be too small to identify significant differences. […] However, from a clinical practice point of view, incorporating the assessment of inflammatory indices into LACC management could be beneficial but at the moment, given the variability of scientific evidence, it would also seem premature. […] Therefore, based on the available reports, the most promising candidate for inclusion in predictive models seem to be the NLR, given the significant prognostic impact recorded in several analyses, even though not confirmed in others and our study.

• #10 Nomogram prediction for overall survival of patients diagnosed with cervical cancer | British Journal of Cancer

  https://www.nature.com/articles/bjc2012340

  Accurate prediction of cancer control after definitive treatment for cervical cancer is important for patient counselling, follow-up, and treatment planning. […] The nomogram can be used to predict patients prognosis individually and more accurate than FIGO stage alone and is based on the following six easily available parameters: FIGO stage, tumour size, histologic type, LNR, age, and parametrial involvement. […] This nomogram is the first to predict OS through stages IIV that was constructed based on data of a mainly Caucasian patient cohort. […] In summary, we present the first model to predict 3- and 5-year survival for patients with cervical cancer after surgical staging that is applicable through stages IIV.

• #10 Nomogram prediction for overall survival of patients diagnosed with cervical cancer | British Journal of Cancer

  https://www.nature.com/articles/bjc2012340

  Nomograms are predictive tools that are widely used for estimating cancer prognosis. The aim of this study was to develop a nomogram for the prediction of overall survival (OS) in patients diagnosed with cervical cancer. […] Mean 5-year OS rates for patients with International Federation of Gynecologists and Obstetricians (FIGO) stage IA, IB, II, III, and IV were 99.0%, 88.6%, 65.8%, 58.7%, and 41.5%, respectively. […] The prognostic performance of the model exceeded that of FIGO stage alone and the models estimated optimism-corrected concordance probability was 0.723, indicating accurate prediction of OS. […] Based on six easily available parameters, a novel statistical model to predict OS of patients diagnosed with cervical cancer was constructed and validated. […] The model was implemented in a nomogram and provides accurate prediction of individual patients prognosis useful for patient counselling and deciding on follow-up strategies.

• #11 New Nomogram Enhances Cervical Cancer Prognosis Prediction

  https://bioengineer.org/new-nomogram-enhances-cervical-cancer-prognosis-prediction/

  Additionally, the studys robust analysis revealed that age, histological type, and disease stage are independent prognostic factors for overall survival. […] Validation of the nomograms accuracy is another notable accomplishment of the study. […] In conclusion, the development of this nomogram represents a significant advancement in the management of cervical cancer. […] This study provides compelling evidence that disease staging and histopathological type are the most critical determinants of prognosis, paving the way for targeted therapeutic strategies. […] The implications of the research encapsulate a broader narrative of advancing healthcare through evidence-based practices. […] This research underscores the critical need for continued investigation into cancer prognostication and personalized treatment strategies.

• #11 New Nomogram Enhances Cervical Cancer Prognosis Prediction

  https://bioengineer.org/new-nomogram-enhances-cervical-cancer-prognosis-prediction/

  Cervical cancer remains a significant threat to womens health worldwide, ranking as the third most common malignancy among women. […] a recent study has sought to enhance our understanding of cervical cancer prognosis and survival through robust statistical models. […] Among its remarkable findings is the development of a nomogram designed to predict the long-term prognosis of cervical cancer patients, making it a pivotal step in personalized medical approaches. […] The findings elucidated in this study offer critical insights into how different variables influence overall survival in cervical cancer patients. […] This nomogram is particularly noteworthy as it forecasts overall survival rates at various intervals: 1, 3, 5, and even 10 years post-diagnosis. […] One of the striking results of the study is the high overall survival rates observed among cervical cancer patients in Mato Grosso.

• #12 Prognosis and survival for cervical cancer | Canadian Cancer Society

  https://cancer.ca/en/cancer-information/cancer-types/cervical/prognosis-and-survival

  Younger women tend to have a better outlook than older women. Women who have good general health other than the cancer also tend to have a better prognosis. […] Women with anemia seem to have a poorer outcome than women who do not have anemia. Women with anemia also dont respond as well to radiation therapy. […] Women who smoke tend to have a poorer prognosis than women who dont smoke. […] Women who have human immunodeficiency virus (HIV) tend to have aggressive cervical cancer with a poor prognosis. […] Unlike with most cancers, it is unclear if grade has a role in determining prognosis in women with cervical cancer. Some studies have shown that higher grades of cervical cancer are linked with poorer outcomes but other studies have not shown the same link.

• #13 Radiomic profiles improve prognostication and reveal targets for therapy in cervical cancer | Scientific Reports

  https://www.nature.com/articles/s41598-024-61271-4

  Advanced FIGO 2018 stage (III/IV) and high age (years) also predict poor disease-specific survival with HRs of 4.52 (95% CI 2.04-10.03, p<0.001) and 1.03 (95% CI 1.00-1.05, p=0.02), respectively. [...] In a multivariable analysis, including Cluster (2/3 vs 1), age (years) and FIGO 2018 stage (III/IV vs I/II), Cluster 2/3 independently predicts poor outcome (adjusted HR of 2.51, 95% CI 1.02-6.16; p=0.045; Table 1). [...] This study demonstrates that whole-volume magnetic resonance imaging (MRI) radiomic tumor profiling captures microstructural tumor features that are closely linked to clinical characteristics and outcomes in patients with uterine cervical cancer. [...] Altogether, this information may inform the selection of patients for more individualized and targeted treatment schemes (e.g., tailored surgery, radio-chemotherapy, immunotherapy, CDK4/6 and YAP-TEAD inhibitors, and p53 pathway-targeting treatments).

• #13 Radiomic profiles improve prognostication and reveal targets for therapy in cervical cancer | Scientific Reports

  https://www.nature.com/articles/s41598-024-61271-4

  Cervical cancer (CC) is a major global health problem with 570,000 new cases and 266,000 deaths annually. Prognosis is poor for advanced stage disease, and few effective treatments exist. […] This retrospective cohort study demonstrates how non-invasive, preoperative, MRI radiomic profiling may improve prognostication and tailoring of treatments and follow-ups for cervical cancer patients. […] By linking their radiomic profiles to genomic alterations, we identify putative treatment targets for the different patient clusters (e.g., immunotherapy, CDK4/6 and YAP-TEAD inhibitors and p53 pathway targeting treatments). […] Patients in Cluster 2 and 3 had significantly poorer disease-specific survival than patients in Cluster 1, both when including all histologies (n=132) (p=0.009; Fig. 2b), and within the subgroup of squamous cell carcinomas (n=103) (p=0.02; Fig. 2c).

• #14

  https://link.springer.com/article/10.1007/s12672-022-00551-9

  As the fourth most diagnosed cancer, cervical cancer (CC) is one of the major causes of cancer-related mortality affecting females globally, particularly when diagnosed at advanced stage. […] The poorer prognosis and ineffective treatment in the advance stage of CC necessitate the development of new prognostic, diagnostic, and therapeutic strategies. […] The discovery of biomarkers including genes, DNA, RNA, proteins, enzymes, antigens, and other cellular and biological products paves the road to precision medicine for better patient outcomes through the classification of patients by probable disease risk, treatment and prognosis. […] Thus, identification of CC biomarkers is expected to provide greater direction in strategizing the prevention and treatment of CC. […] Biomarkers can also be applied to estimate the prognosis of patients, to determine the treatment impact, and to monitor the treatment progression.

• #15

  https://link.springer.com/article/10.1007/s12672-022-00551-9

  Biomarkers play a role in the development of precision medicine as the treatments to individual or subgroups of patients can be adjusted based on specific biomarkers for optimal patient outcomes. […] The persistent infection with hrHPV causes viral integration into the host genome up to 76.3% of CC cases with positive correlation to CIN grades, which can be detected with NGS. […] Therefore, the HPV integration status may consider as a promising biomarker for diagnosis, risk stratification, therapy, prediction of treatment responses and treatment monitoring. […] A combination of six upregulated oncogenic miRNAs (miR-20a, miR-92a, miR-141, miR-183*, miR-210 and miR-944) showed enhanced accuracy for diagnosis of CC compared with individual use of any marker with an excellent AUC of 0.959, sensitivity of 91.4%, and specificity of 87.6%.

• #16

  https://link.springer.com/article/10.1007/s12672-022-00551-9

  The elevated expression of PCBP1-AS1 is associated with tumor stage, TNM and invasion. […] The significantly elevated levels of serum SCC-Ag, highly sensitive C-reactive protein (hs-CRP), and CA-125 in recurrence cervical patients indicates that these proteins could be potential biomarkers for the prediction of recurrence risk. […] A recent meta-analysis concluded elevated expressions of VEGF and VEGF-C were significantly associated with poor survival outcome in patients with CC. […] The ratio of serum angiopoietin-1 to angiopoietin-2 in patients with cervical cancer is a valuable diagnostic and prognostic biomarker. […] The limitations of current screening and diagnostic strategies for CC prompt the development of novel biomarkers to improve the clinical outcomes of CC patients. […] Improved patient care can be achieved with co-evolvement of high throughput analyses and biomarker-based precision medicine.

• #17 Prediction of Cervical Cancer Outcome by Identifying and Validating a NAD+ Metabolism-Derived Gene Signature

  https://www.mdpi.com/2075-4426/12/12/2031

  Cervical cancer (CC) is the second most common female cancer. Excellent clinical outcomes have been achieved with current screening tests and medical treatments in the early stages, while the advanced stage has a poor prognosis. […] This study set out to identify an NAD+ metabolic-related gene signature for the prospect of cervical cancer survival and prognosis. […] The 21-gene signature was significantly different between the low- and high-risk groups in the training and validation datasets. Our work revealed the promising clinical prediction value of NAD+ metabolic-related genes in cervical cancer. […] However, for the advanced stage, the unoptimistic prognosis is ascribed to a lack of timely and accurate measures depending on the clinical condition of patients. […] Hence, there is an urgent need to identify biomarkers of progression to reverse the outcome of CC.

• #18 Prediction of Cervical Cancer Outcome by Identifying and Validating a NAD+ Metabolism-Derived Gene Signature

  https://www.mdpi.com/2075-4426/12/12/2031

  The survival analysis illustrated that the high-risk group had a significantly worse PFI and OS compared with those of the low-risk group in both the training and validation cohorts. […] The predicated model showed a strong predictive performance, and the survival rates of the low-risk group were significantly higher than those of the high-risk group. […] The results of the multivariate analysis in different datasets clarified that the NAD+ metabolic-related signature is an independent factor after adjusting for other clinical factors (including age, FIGO stage, tumor size, lymph node status, metastasis status, and risk group). […] This study demonstrates a new NAD+ metabolism-related prognostic model and therapeutic target for cervical cancer.

• #19 Machine learning-based prediction of survival prognosis in cervical cancer | BMC Bioinformatics | Full Text

  https://bmcbioinformatics.biomedcentral.com/articles/10.1186/s12859-021-04261-x

  Accurately forecasting the prognosis could improve cervical cancer management, however, the currently used clinical features are difficult to provide enough information. […] A miRNAs-based machine learning cervical cancer survival prediction model was developed that robustly stratifies cervical cancer patients into high survival rate (5-years survival rate90%), moderate survival rate (5-years survival rate 65%), and low survival rate (5-years survival rate40%). […] Survival prediction after first diagnosis is important for both disease specialist and patients or their family members. […] The cervical cancer patients were optimally clustered into four groups with three different 5-years survival outcome (90%, 65%,40%) by K-means clustering algorithm base on top 10 survival-related miRNAs.

• #20 Machine learning-based prediction of survival prognosis in cervical cancer | BMC Bioinformatics | Full Text

  https://bmcbioinformatics.biomedcentral.com/articles/10.1186/s12859-021-04261-x

  The results of this study would improve the forecasting capacity of CCSPM and be helpful for cervical cancer management. […] The model exhibited high performance: AUC value=0.956 (group 1), 0.914 (group 2), 0.968 (group 3), 0.968 (group 4) for test set; 0.987 (group 1), 0.986 (group 2), 1.000 (group 3), 0.996 (group 4) for training set; 0.978 (group 1), 0.964 (group 2), 0.990 (group 3), 0.988 (group 4) for whole set, and the misdiagnosis rate was 6.52% (test set), 0.93% (training set), 2.61% (whole set), respectively. […] Collectively, a miRNAs-based ML CCSPM that stratifies cervical cancer patients into high survival rate (5-years survival rate90%), moderate survival rate (5-years survival rate 65%) and low survival rate (5-years survival rate40%) was developed.

• #21 Prediction of 10-year Overall Survival in Patients with Operable Cervical Cancer using a Probabilistic Neural Network

  https://www.jcancer.org/v10p4189.htm

  Background: Toward the goal of predicting individual long-term cancer survival to guide treatment decisions, this study evaluated the ability of a probabilistic neural network (PNN), an established model used for decision-making in research and clinical settings, to predict the 10-year overall survival in patients with cervical cancer who underwent primary surgical treatment. […] Conclusion: The PNN model effectively and reliably predicted 10-year overall survival in women with operable cervical cancer, and may therefore serve as a tool for decision-making process in cancer treatment. […] The applied PNN model was used to predict the 10-year overall survival in cervical cancer patients treated with radical hysterectomy. The error, sensitivity, and specificity for the PNN were markedly better than those obtained by the LR model. […] Our model could predict 10-year overall survival in cervical cancer patients with an error of 12.5%.

• #22 Classical Prognostic Factors Predict Prognosis Better than Inflammatory Indices in Locally Advanced Cervical Cancer: Results of a Comprehensive Observational Study including Tumor-, Patient-, and Treatment-Related Data (ESTHER Study)

  https://pmc.ncbi.nlm.nih.gov/articles/PMC10456032/

  Systemic inflammation indices were found to be correlated with therapeutic outcome in several cancers. This study retrospectively analyzes the predictive role of a broad range of systemic inflammatory markers in patients with locally advanced cervical cancer (LACC) including patient-, tumor-, and treatment-related potential prognostic factors. […] The multivariate analysis showed only the significant correlation between higher SII values and lower DMFS rates (p 0.01). Our analysis showed no significant correlation between indices and DSF or OS. […] In order to improve the outcome prediction, and therefore to allow treatment modulation based on the prognostic profile, recent investigations evaluated the predictive role of several systemic inflammation indices which were found to be significantly correlated with the therapeutic outcome in several cancers.

• #22 Classical Prognostic Factors Predict Prognosis Better than Inflammatory Indices in Locally Advanced Cervical Cancer: Results of a Comprehensive Observational Study including Tumor-, Patient-, and Treatment-Related Data (ESTHER Study)

  https://pmc.ncbi.nlm.nih.gov/articles/PMC10456032/

  In terms of inflammation indices, our multivariate analysis confirmed only a significant correlation between increasing SII values and worse DMFS, in contrast to other studies reporting a significant correlation between pretreatment indices values and DFS and OS. […] Therefore, based on the available reports, the most promising candidate for inclusion in predictive models seem to be the NLR, given the significant prognostic impact recorded in several analyses, even though not confirmed in others and our study.

• #23 Identification of immune-related cervical cancer prognostic biomarkers and construction of prognostic model based on tumor microenvironment | European Journal of Medical Research | Full Text

  https://eurjmedres.biomedcentral.com/articles/10.1186/s40001-025-02515-5

  Tumor microenvironment (TME) and the expression of immune-related genes (IRGs) are closely related to the development of cervical cancer (CC). This study aims to explore some IRGs as prognostic biomarkers for CC patients based on TME. […] The signature of the five IRGs was identified to be an independent prognostic indicator for the overall survival in CC patients. A prognostic risk model was also constructed. CC patients were classified into high- and low-risk groups based on the median risk score. The survival time of patients in the high-risk group was shorter than that of those in the low-risk group. […] Immune-related prognostic biomarkers in CC include HLA-DMA, DMBT1, CXCR6, CX3CL1, and SEMA3A. The risk score for the five genes is more accurate than that for other clinical risk factors in predicting prognosis at 3 and 5 years. The higher the risk score is, the worse the prognosis of CC patients is.

• #24 Identification of pyroptosis-related signature for cervical cancer predicting prognosis | Aging

  https://www.aging-us.com/article/203716/text

  The DCA further demonstrated the clinical usefulness of the signature. […] This finding is consistent with previous studies that concluded that patients with high TME scores exhibited a stronger anti-tumor immune response, stood to benefit more from immunotherapy, and survive longer. […] In our study, GZMB, which is a component of the prognostic model, was significantly upregulated in CC tissues. […] The GZMB/miR-378a/TRIM52-AS1 regulatory axis that has a strong correlation to the development of CC was extracted from the mRNA-miRNA-LncRNA interaction network. […] This is expected to be relevant in the theoretical study of molecular mechanisms and for assessing the prognosis of cervical cancer patients.

Zobacz więcej